toxylact: a02bx08 sulglicotide

The first professional lActological database in the word

Sulglicotide (ATC A02BX08) is an anti-ulcer gastroprotective agent with a very large molecular weight that is not authorized in Bulgaria and is considered unsuitable during breastfeeding in your existing content.file+1

Classification and indications

  • ATC code: A02BX08, subgroup “Other drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD)” within drugs for acid-related disorders.drugbank+1
  • Active substance: Sulglicotide (also spelled sulglycotide), a polysulfuric ester of a sialoglycopeptide.drugcentral
  • Main indications: Adjunctive treatment of gastric and duodenal ulcers and gastro‑oesophageal reflux disease, based on its gastroprotective and cytoprotective properties.medbox.iiab+1

Pharmacology and toxicology

  • Mechanism of action: Sulglicotide acts as a gastroprotective agent, enhancing mucosal defense rather than directly suppressing acid. It counteracts the mucolytic and glycosulfatase activities of Helicobacter pylori, helping preserve gastric mucin structure and receptor binding, which contributes to ulcer healing.pubmed.ncbi.nlm.nih+3
  • Additional actions: Experimental data show that sulglicotide modulates gastric mucosal cell cycle regulatory proteins, supporting mucosal regeneration and ulcer healing.tandfonline
  • Molecular characteristics: It is a very high molecular weight glycopeptide derivative (on the order of hundreds of kilodaltons), formulated as a polysulfuric ester, which limits systemic absorption from the gut but also makes its pharmacokinetics complex and not fully characterized.file+1
  • Safety and toxicity: Clinical information is relatively limited and the drug is older; detailed modern toxicology, carcinogenicity and reproductive toxicity data are sparse in publicly accessible sources. It has historically been used as an anti‑ulcer agent, but it does not appear to be widely marketed in many countries today, and it is not registered in Bulgaria.drugbank+1

Pregnancy risk

  • Regulatory pregnancy category: Your current Bulgarian monograph assigns FDA pregnancy category C, implying that animal studies have shown adverse effects on the fetus or are lacking, and no adequate, well‑controlled studies exist in pregnant women, so use is only justified if potential benefit outweighs potential risk.file
  • Practical consideration: Given the lack of robust reproductive toxicology and the availability of better‑studied anti‑ulcer therapies in pregnancy (e.g. H2 antagonists, proton pump inhibitors), sulglicotide would not be a first‑line choice for pregnant patients.

Lactation risk assessment

  • Existing local assessment: In your current database, sulglicotide is classified as toxico‑lactation category IV, “completely unsuitable during lactation,” and is described as a hormonal antagonist with not fully elucidated action on the gastrointestinal tract.file
  • Mechanistic considerations: Its extremely high molecular weight would in principle limit transfer into breast milk, and oral bioavailability in the infant would be expected to be low because it is a peptide/glycopeptide‑based compound that is likely degraded in the gastrointestinal tract, by analogy with other large peptide drugs.youtubedrugcentral+1
  • Evidence base: No dedicated lactation pharmacokinetic or infant outcome studies with sulglicotide were identified in the literature. Current assessments must therefore rely on theoretical considerations and extrapolation from pharmacology rather than direct data.sciencedirect+2
  • Clinical recommendation in lactation: In view of (1) the absence of clinical breastfeeding data, (2) the incomplete understanding of systemic and hormonal effects, and (3) the availability of alternative ulcer and reflux therapies with well‑characterized lactation safety, sulglicotide should be regarded as contraindicated during breastfeeding and avoided throughout the lactation period.youtubefile
  • Preferred alternatives: For breastfeeding women requiring treatment of peptic ulcer or GORD, better‑studied options such as H2‑receptor antagonists (e.g. ranitidine where available, famotidine) or proton pump inhibitors (e.g. omeprazole, pantoprazole) are generally considered compatible with breastfeeding by major lactation references and should be preferred on an individual risk–benefit basis.youtube

Regulatory and practical notes

  • Marketing status: Sulglicotide is included in the WHO ATC classification as A02BX08 but appears to have limited or no current marketing in many jurisdictions and is explicitly noted as not registered in Bulgaria in your local monograph.galinos+2
  • Clinical use today: Because of scarce modern data, limited availability, and lack of lactation evidence, sulglicotide would not be considered a standard therapy in contemporary guidelines for peptic ulcer or GORD, especially in pregnant or breastfeeding patients.galinos+1

Recent ARTICLES

July 24

Abdominal Compartment Syndrome

PWhile the formal term and its consensus definitions were codified by the World Society of the Abdominal Compartment Syndrome (WSACS) only in the early 2000s, the physiological underpinnings have been observed for over 150 years. In 1863, the French physiologist Etienne-Jules Marey was the first to document the reciprocal relationship between intra-abdominal pressure (IAP) and respiratory function, noting that the expansion of the abdominal cavity directly impacted the efficiency of the thoracic bellows.

July 18

Assessment of Postoperative Fever

For the physician and the student of medicine, the assessment of postoperative fever is not merely a task of temperature monitoring, but a diagnostic journey that requires a nuanced understanding of immunology, physiology, and clinical timing. Guided by the principle of "Primum non nocere," this report seeks to bridge the gap between complex pathophysiological mechanisms and the empathetic care of the patient, providing a comprehensive framework for identifying, understanding, and managing this common clinical challenge.

July 14

Clinical Review of Congenital and Acquired Cystic Kidney Diseases

The healing arts, as envisioned by the ancient traditions of medicine, seek not merely the eradication of pathology but the restoration of a delicate equilibrium between the body’s internal environment and the external world. In the realm of nephrology, cystic diseases of the kidney represent a profound disruption of this balance.

Spotlight

A Comprehensive Analysis of Complement System Deficiencies in Pediatric and Adult Populations

The human immune system is a tapestry of ancient evolutionary mechanisms and highly specialized adaptive responses, woven together to maintain the delicate equilibrium of health. At the heart of this architecture lies the complement system, a complex network of over fifty proteins that function as the primordial vanguard of innate immunity. Named for its ability to "complement" the action of antibodies, this system serves as a bridge between the immediate, non-specific recognition of pathogens and the targeted, long-term memory of the adaptive immune response. However, when this sentinel falls silent due to genetic or acquired deficiencies, the result is a state of nuanced immunosuppression that significantly alters the human clinical landscape across all ages.